TABLE 1.

Summary of therapeutic evaluation of PG-11157 and fumagillin in SCID mice challenged with E. bieneusi spores

Mouse group	No. of mice	E. bieneusi spore challenge dose	Drug (treatment [mg/kg/day])	% Inhibitiona
				At end of treatment with PG-11157	On the week following anti-IFN-γ antibody injection
1	5	0	PG-11157 (150)b	100	100
2	6	104	Placebo	0	0
3	7	104	Fumagillin (1)c	93.7	−6.1
4	7	104	PG-11157 (150)	99.6	75.8
5	7	104	PG-11157 (75)d	99.5	43.1
6	7	104	PG-11157 (10)e	−20	−59.8

^aPercent inhibition is the percent reduction in the average level of spore excretion in feces at the end of drug treatment and the week after the end of the experiment compared with the level of spore excretion in feces in the placebo-treated group.

^bPG-11157 was given orally twice daily (150 mg/kg/day) for 7 days.

^cFumagillin was given orally once daily (1 mg/kg/day) for 7 days.

^dPG-11157 was given orally once daily (75 mg/kg/day) for 7 days.

^ePG-11157 was given i.p. twice over a week (10 mg/kg/injection).